EN DE
Watch CelLBxHealth plc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CelLBxHealth plc (CLBX) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of CelLBxHealth plc stock £0.01, price £0.01, that is 0.7% below the price, quality 25 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB

CP CelLBxHealth plc logo Thin data Nov 10, 2026

CelLBxHealth plc

CLBX · LSE

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value £0.0060 · Fairly valued 
Expensive Growth (revenue 3y +9.1 %/yr in GBP) 
Revenue last quarter 25% below a year ago. 
Quality 25/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch CelLBxHealth plc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£1.56 £0.0060 Fair Value £0.0060 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £0.0060 – £1.56 · fair‑value band £0.0059 – £0.0060 · the £0.0060 price screens above the £0.0060 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CelLBxHealth in your weekly email

Every Wednesday you see whether CelLBxHealth is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally.

Show moreShow less

The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood.

It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology.

In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays.

CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel.

The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Stock analysis

CelLBxHealth plc (CLBX) currently trades at £0.0060, while our estimate is £0.0060, so the stock looks roughly fairly valued today (gap 0.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.0059 (bear) to £0.0060 (bull), the price of £0.0060 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

CelLBxHealth plc reported revenue of £1.4M in FY2025 versus £1.0M in FY2021, a compound +7.5%/yr. Reported net income was −£19.5M in FY2025.

Key figures

Market cap £6.8M Micro · P/S ratio 6.17 · EPS (TTM) £−0.0300 · Return on equity −164% · Return on assets (EBIT) −67.6% (5-year average) · Operating margin −444% · Revenue (TTM) £1.2M · Revenue growth (YoY) −25.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 72% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −1%, CLBX screens cheaper than that median.

Fair Value

Bear £0.0059 Fair Value £0.0060 Bull £0.0060
Price £0.0060 · Downside -0.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 70
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−52.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,710.5% (2021) → −1,140.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CLBX, get fair value alerts →

Compare CelLBxHealth plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −0.7% · Above median
Profitability
Return on assets −155.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −25.0% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.95× · Cheapest 25%
P/S (12 months) 5.92× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)32 · sector 12
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 8
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥146.30 ¥165.37 +13% vs CLBX
IQVIA Holdings IQV $265.12 $299.58 +13% vs CLBX
Illumina, Inc ILMN $207.01 $227.71 +10% vs CLBX
Thermo Fisher Scientific Inc TMO $700.22 $686.04 −2% vs CLBX
Danaher Corporation DHR $233.02 $209.18 −10% vs CLBX
IDEXX Laboratories, Inc IDXX $704.23 $496.48 −30% vs CLBX
Lonza Group LONN CHF 666.00 CHF 259.80 −61% vs CLBX
Mettler-Toledo International Inc MTD $1,739 $655.06 −62% vs CLBX
Agilent Technologies, Inc A $173.96 $64.53 −63% vs CLBX
Waters Corporation WAT $460.25 $91.26 −80% vs CLBX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CelLBxHealth plc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CelLBxHealth plc Fair Value". https://www.fairvalue-calculator.com/stock/CLBX

Frequently asked questions

Is CelLBxHealth plc (CLBX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.0060 versus a price of £0.0060, about 1% lower (fairly valued).
What is the fair value of CLBX?
Our estimate for CelLBxHealth plc is £0.0060 (as of Nov 10, 2026), built from audited fundamentals. The current price: £0.0060.
What is the quality score of CLBX?
CelLBxHealth plc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CelLBxHealth plc (CLBX)?
Our calculated price target is the estimate of £0.0060 (as of Nov 10, 2026). Cautious scenario £0.0059, optimistic scenario £0.0060. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CelLBxHealth plc stock forecast for 2026?
Our estimate puts fair value at £0.0060, about 1% lower versus a price of £0.0060 (fairly valued). Cautious scenario £0.0059, optimistic scenario £0.0060. The calculation is refreshed regularly with new filings.
What is the revenue of CelLBxHealth plc (CLBX)?
CelLBxHealth plc reported trailing-twelve-month revenue of about £1.2M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CelLBxHealth plc (CLBX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CelLBxHealth plc it is £0.0060 per share (as of Nov 10, 2026), against a price of £0.0060.
Is CelLBxHealth plc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CLBX trades above its calculated fair value: price £0.0060, fair value £0.0060, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLBX?
No. The price is what the market pays today (£0.0060); the fair value is what the company's own numbers justify (£0.0060). For CelLBxHealth plc the two are £0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is CelLBxHealth plc worth?
The market values CelLBxHealth plc at about £6.8M (market capitalisation, as of Nov 10, 2026). Per share that is £0.0060; our models calculate a fair value of £0.0060 per share.
What do the bullish and bearish scenarios say about CLBX?
Our models span a range for CelLBxHealth plc: cautious scenario £0.0059, base £0.0060, optimistic £0.0060 per share (as of Nov 10, 2026, price £0.0060). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CelLBxHealth plc (CLBX)?
Balance-sheet figures for CelLBxHealth plc (as of Nov 10, 2026): return on equity −163.8%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is CLBX from its 52-week high?
CelLBxHealth plc trades at £0.0060, about 72% below its 52-week high of £0.0215 and at the low of £0.0060 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0060 is for.
Which stocks are comparable to CelLBxHealth plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CelLBxHealth plc stock attractive at the current price?
The data as of Nov 10, 2026: price £0.0060, calculated fair value £0.0060 (−1%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. CelLBxHealth plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CelLBxHealth plc (CLBX)?
The closing price on Nov 13, 2026 was £0.0060. Our estimate is £0.0060, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CelLBxHealth plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (£0.0059 to £0.0060), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of CelLBxHealth plc

How large is the market capitalisation of CelLBxHealth plc (CLBX)?
The market capitalisation of CelLBxHealth plc is £6.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CelLBxHealth plc (CLBX)?
The price-to-sales ratio of CelLBxHealth plc is 6.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CelLBxHealth plc (CLBX)?
Earnings per share at CelLBxHealth plc are £−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CelLBxHealth plc (CLBX)?
The return on equity (ROE) of CelLBxHealth plc is −164% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CelLBxHealth plc (CLBX)?
On an EBIT basis the return on assets of CelLBxHealth plc is −67.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CelLBxHealth plc (CLBX)?
The operating margin of CelLBxHealth plc is −444% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CelLBxHealth plc (CLBX)?
Revenue at CelLBxHealth plc is down 25.0% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CelLBxHealth plc (CLBX) generate?
The free cash flow of CelLBxHealth plc is −£9.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch CelLBxHealth plc in the live analysis

One click puts CelLBxHealth plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.